Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
Genentech, Inc.
Amgen
Upon determination of eligibility, patients will receive:
* Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + Rituximab
Patients that are not considered candidates for anthracycline therapy will not receive mitoxantrone. Patients with objective response (partial or complete response) or stable disease will receive Rituximab maintenance therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
To be included in this study, you must meet the following criteria:
Histologically documented large B-cell, CD20-positive non-Hodgkin's lymphoma
No previous treatment
Clinical stage II, III, or IV by the Ann Arbor Staging Criteria
Age \> 70 years
ECOG performance status 0, 1, or 2
Adequate bone marrow, liver and kidney function
Must give written informed consent prior to entering this trial
You may not be if
You cannot participate in this study if any of the following apply to you:
Age \< 18 years
Central nervous system involvement with lymphoma
Coexistent active malignancies treated within five years
Active infection precluding the use of combination chemotherapy
